Kurt Mathas to Discuss Reference Drug Patent Challenges at 15th Annual Summit on Biosimilars & Innovator Biologics

Winston & Strawn partner Kurt Mathas will speak at the 15^thSummit on Biosimilars & Innovator Biologics, June 20-21, 2024, in New York. The summit—which attracts the “who’s who” of the industry, including leading in-house counsel from branded and biosimilar companies, representatives from key government agencies, and the top patent and regulatory attorneys—will cover legal, regulatory, and commercial strategies for the innovator and biosimilars marketplace.

Kurt’s panel “Reference Drug Patent Challenges: Unpacking Recent IPR Decisions and Insights” will cover:

• Recent cases that impact the patentability of biologics, e.g., Amgen v. Sanofi, Kite v. Juno, and recent subject matter eligibility case law;
• The advantages for applicants to resolve prior art invalidity disputes via IPRs;
• Establishing standing to appeal in an IPR in connection with BPCIA and the FDA approval process for biosimilars;
• The timing for applicants to file petitions for IPRs relative to filing BLAs and BPCIA litigation;
• Biosimilars IPR filings and recent PTAB decisions, e.g., the PTAB challenges relating to SOLIRIS and STELARA

Learn more and register.

Learn more about Winston’s Patent Litigation Practice.